Nautilus Biotechnology (NasdaqGS:NAUT) Conference March 25, 2026 01:00 PM ET Company ParticipantsAnna Mowry - CFOSujal Patel - Founder and CEOSujal PatelHello, everyone. I'm Sujal Patel, Founder and CEO of Nautilus Biotechnology, and I'm joined with by Anna Mowry, our Chief Financial Officer. We're here to talk about Nautilus unlocking the power of the proteome to revolutionize biomedicine. As we begin, this is our standard safe harbor statement. This presentation and my oral remarks have forward-looking st ...

SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference. Nautilus’ management is scheduled to present on Wednesday, March 25, 2026, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the com ...

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit• NIH-funded project leverages collaborators’ expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of ...

Core Perspective - Nautilus aims to position itself within the proteomics ecosystem by addressing key differentiators and challenges in the field of proteomics, particularly in real-time measurement of proteins compared to the established methods of genomic measurement [1] Group 1: Proteomics Context - The company highlights the advancements made in genomic measurement over the past decades, noting that it is now possible to accurately and quickly measure 99.9% of an individual's DNA from a small blood sample [1] - However, the limitation of genomic data is that it remains static throughout a person's life, failing to reflect the dynamic state of biological processes [1] Group 2: Company Differentiation - Nautilus is focused on solving the challenges associated with real-time protein measurement, which is crucial for understanding the current biological state of individuals [1] - The company seeks to differentiate itself by providing solutions that go beyond static genomic data, aiming to capture the complexities of proteomics [1]

Nautilus Biotechnology (NasdaqGS:NAUT) FY Conference March 02, 2026 10:30 AM ET Company ParticipantsSujal Patel - Co-Founder and CEOConference Call ParticipantsDan Brennan - Life Science Tools and Diagnostics AnalystDan BrennanGood morning. Dan Brennan, TD Cowen Life Science Tools and Diagnostics Analyst. Day one of the 46th annual TD Cowen Healthcare Conference. Pleased to be joined here on the stage with Co-founder and CEO of Nautilus, Sujal Patel. Sujal, welcome and thank you.Sujal PatelThanks, Dan, and ...

Core Insights - Nautilus Biotechnology, Inc. has appointed Amber Faust as Vice President of Sales to enhance the commercial progress of its Voyager Platform, which focuses on single-molecule proteome analysis [3][5][6] Company Developments - The Voyager Platform has recently been launched, featuring Iterative Mapping technology that allows for single-molecule analysis of proteins and proteoforms [3][5] - The company is preparing for the commercial launch of the Voyager Platform in late 2026, which includes securing pre-orders and managing installations [5][6] - The Nautilus Tau Proteoforms assay is currently in use at the Buck Institute for Research on Aging, mapping up to 768 distinct tau proteoform groups [5] Leadership and Expertise - Amber Faust brings nearly two decades of experience in life sciences, having held significant roles at companies like Olink Proteomics and SomaLogic [4][6] - Faust's background includes a Master of Science in Biomedical Science and a Bachelor of Science in Biology and Chemistry, emphasizing her expertise in the field [6] Technology Overview - The Voyager Platform utilizes a proprietary Iterative Mapping approach, capable of measuring up to 10 billion intact protein molecules, which allows for a wide dynamic range in analysis [7] - The platform employs machine learning algorithms to convert probe-binding patterns into protein and proteoform identifications, facilitating detailed analysis [7][8]

Business Combination and Financial Overview - Nautilus Biotechnology completed a business combination on June 9, 2021, resulting in the issuance of 20,000,000 shares of common stock for gross proceeds of $200 million[27]. - The company has incurred net losses in every period to date and expects to continue incurring significant losses as it develops its business, indicating a risk of never achieving profitability[199]. - The company incurred net losses of $59.0 million and $70.8 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $332.0 million as of December 31, 2025[215]. - The company may need to raise additional capital to fund its development and commercialization plans, which may not be available on favorable terms[203]. - The company expects to incur significant legal, accounting, and operational expenses as a public entity, impacting future profitability[215]. Market Potential and Growth - The global proteomics research market is projected to grow to approximately $57 billion by 2030, with a compound annual growth rate (CAGR) of about 13%[31]. - The global proteomics market is projected to reach approximately $57 billion by 2030, with an estimated CAGR of 13% from 2025 to 2030[68]. - Approximately 95% of FDA-approved drug targets are proteins, emphasizing the importance of understanding the proteome in pharmacology[55]. - The application of proteomic technologies to clinical specimens is expected to revolutionize diagnosis and treatment in biomedical sciences, driven by biomarker discovery[69]. Nautilus Voyager Platform Features - Nautilus Voyager platform aims to decode and quantify approximately 95% of the entire proteome, integrating instrumentation, consumables, and software into a single platform[43]. - The Nautilus Voyager platform is designed to generate single-molecule counts, providing high reproducibility and enabling integration with other biological methods[40]. - The Nautilus Voyager platform is expected to produce vast amounts of proteomic data, which will be enhanced through proprietary machine learning algorithms[43]. - The Nautilus Voyager platform aims to enable comprehensive, reproducible, and scalable proteome quantification, including the characterization of proteoforms[77]. - The platform is designed to process biological samples and generate proteomic data, supporting downstream biological analysis and interpretation[78]. - The Nautilus Voyager platform incorporates an integrated workflow that supports single-molecule detection, enhancing sensitivity and dynamic range for low-abundance proteins[86]. - The platform's design allows for targeted proteoform analysis using off-the-shelf affinity reagents, enabling detection of specific protein forms and modifications[99]. - The Nautilus Voyager platform can identify proteins using approximately 300 unique multi-affinity reagents, enabling broadscale proteomics[102]. - The platform is designed to detect as few as 1 protein molecule in 1,000 cells, addressing the challenge of identifying rare but biologically significant proteins[117]. - The Nautilus Voyager platform aims to create a comprehensive dataset of proteoforms, with estimates suggesting up to 6 million different proteoforms exist due to protein modifications[119]. Commercialization Strategy - The commercialization strategy includes a phased approach, starting with an "Iterative Mapping Early Access Program" launched in January 2026[40]. - Nautilus plans to execute a land-and-expand commercialization strategy, allowing customers to adopt either broadscale or targeted proteoform applications on the same platform[45]. - The company anticipates recurring revenue from consumable sales, instrumentation service, support, and software as part of its comprehensive proteomics solution[43]. - The initial commercial model will incorporate Nautilus Proteomics Analysis Services alongside instrument placements, supporting early use cases and maintaining quality control[150]. - The commercial launch is planned for late 2026, with pre-orders for the Nautilus Voyager platform and installations expected to begin in early 2027[151]. - The Early Access Program launched in January 2026 allows select customers to access Iterative Mapping for quantitative analysis of tau proteoforms[146]. - The company aims to commercialize initially in North America, with international expansion anticipated as adoption grows[153]. Research Collaborations and Partnerships - The company has established research collaborations with Genentech, the Michael J. Fox Foundation, and Weill Cornell Medicine–Qatar, among others, to validate platform capabilities and support application development[48]. - The company entered into a research collaboration with Genentech in December 2020 to study proteoforms of the Tau protein, a key biomarker for neurodegenerative diseases[155]. - In February 2025, the company collaborated with The Buck Institute for Research on Aging to utilize the Nautilus Voyager platform for proteoform analysis of Tau protein across multiple projects[155]. - A partnership with The Michael J. Fox Foundation for Parkinson's Research was initiated in January 2026 to develop a single-molecule assay for measuring proteoforms of alpha-synuclein, a protein linked to Parkinson's disease[155]. - Collaborations with academic institutions and biopharmaceutical companies are critical for validating platform performance and generating high-quality biological data[145]. Technical Challenges and Risks - The Nautilus Voyager platform remains in the development stage and is subject to delays, technical challenges, and market acceptance challenges, which could impact commercialization[200]. - The company is dependent on third parties for certain aspects of the development and commercialization of the Nautilus Voyager platform, which poses additional risks[201]. - The success of the Nautilus Voyager platform depends on achieving market acceptance, which requires substantial engagement with the scientific community and key opinion leaders[223]. - The company faces challenges in demonstrating the performance and reliability of the Nautilus Voyager platform compared to existing technologies, which may affect customer adoption[225]. - The commercialization of the Nautilus Voyager platform will require extensive clinical trials to obtain regulatory approvals, which could delay revenue recognition[222]. Regulatory and Compliance Considerations - Products are labeled for research use only and are not intended for clinical diagnostics, which may exempt them from FDA regulation[164]. - Future products may be subject to FDA regulation as medical devices if marketed for clinical diagnostics, requiring significant investment in compliance[166]. - International sales of medical devices will be subject to varying foreign government regulations, particularly under the EU IVDR which aims to enhance the quality and safety of in vitro diagnostic devices[175]. - The company is subject to various federal and state laws and regulations regarding the collection, use, and protection of personal information, which may increase compliance costs[178]. - The company faces risks related to regulatory compliance, including potential future regulation by the FDA and other authorities, which could impact operations[206]. Team and Organizational Structure - Nautilus has a highly interdisciplinary team, with over one-third of employees holding Ph.D. degrees, supporting its strategy for long-term value creation across research and healthcare[41]. - The company employs 130 individuals, with over one-third holding doctorate degrees, and 91 engaged in research and development activities[193]. - The company aims to build a world-class commercial organization focused on delivering value and support throughout the sales cycle, enhancing customer loyalty and driving growth[157]. Competitive Landscape - The life sciences market is highly competitive, with major competitors including Thermo Fisher Scientific, Bruker Corporation, and Illumina, among others[160]. - The company believes it is differentiated from competitors due to its novel high-throughput proteomic technology and rigorous product development processes[161]. - Existing proteomics technologies face limitations in quantification accuracy and reproducibility, complicating integration with genomic and transcriptomic datasets[76].

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2025 were $15.4 million, a decrease of 23% from the prior year period, and $66.8 million for the fiscal year 2025, a decrease of 18% year-over-year [20] - Research and development expenses were $41.1 million for fiscal year 2025, down from $50.5 million in fiscal year 2024, representing a decrease of 19% [20] - Cash burn in 2025 was $50.2 million, down from $57.8 million in 2024, reflecting lower headcount and development expenses [22] Business Line Data and Key Metrics Changes - The early access program for the tau proteoform assay is set to begin processing samples by the end of Q1 2026, with initial customer engagements primarily with academic key opinion leaders [23][24] - The company anticipates modest services revenue later in 2026, with a primary revenue ramp expected to begin in 2027 once instruments start shipping [23] Market Data and Key Metrics Changes - The company is expanding its proteoform capabilities into additional high-value disease targets, including a collaboration focused on alpha-synuclein proteoforms in Parkinson's disease, funded by a $1.6 million project [8][16] - The oncology market is identified as a compelling next opportunity, with plans to evaluate multiple oncology-focused candidate proteins [16] Company Strategy and Development Direction - Nautilus aims to transition from development to active customer engagement, with a focus on commercialization and external validation [5][9] - The company plans to introduce broad-scale capabilities into early access later in 2026 and expects to initiate commercial launch in late 2026 [26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the technical foundation required to scale assays and broaden the target portfolio, reinforcing the belief in the transformative potential of their technology [18][26] - The company anticipates total operating expense growth of approximately 15%-20% in 2026, with cash burn expected to be in the range of $65 million-$70 million [22] Other Important Information - Nautilus unveiled the Voyager instrument at the US HUPO conference, receiving positive feedback from the research community [6][25] - The company has made significant progress in assay development and operational priorities, with a focus on delivering high-quality, commercial-ready products [15][18] Q&A Session Summary Question: What are the next milestones and metrics for improvement? - The completion of the final studies of the tau proteoform assay has been shared with early customers, who are excited about the quality of the assay [30] Question: Will there be any revenue from the commercial launch later this year? - The company anticipates a target of closer to half a million dollars for 2026, with the primary revenue ramp tied to instruments expected in 2027 [39] Question: How is the early access program progressing? - The early access program was launched earlier than planned due to positive early data, and the company is beginning to build its sales capacity [41]

Nautilus Biotechnology (NasdaqGS:NAUT) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Mowry - CFOJi-Yon Yi - Director of Investor RelationsParag Mallick - Co-founder and Chief ScientistSujal Patel - Co-founder and CEOConference Call ParticipantsSubhasis Nambi - Equity Research AnalystNone - AnalystOperatorGood day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. Afte ...

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2025 were $15.4 million, a decrease of 23% from the prior year period, and $66.8 million for the fiscal year 2025, a decrease of 18% year-over-year [18] - Research and development expenses were $41.1 million for fiscal year 2025, down from $50.5 million in fiscal year 2024, representing a decrease of 19% [18] - General and administrative expenses were $25.7 million for fiscal year 2025, compared to $31.0 million in fiscal year 2024, a decrease of 17% [19] - Cash burn in 2025 was $50.2 million, down from $57.8 million in 2024 [21] - The company ended the quarter with $156.1 million in cash equivalents and investments [20] Business Line Data and Key Metrics Changes - The early access program for the tau proteoform assay was launched in January 2026, with initial customer engagements primarily with academic key opinion leaders [22] - The company anticipates modest services revenue later in 2026, with a primary revenue ramp expected to begin in 2027 once instruments start shipping [22] Market Data and Key Metrics Changes - The company is expanding its proteoform capabilities into additional high-value disease targets, including a collaboration focused on alpha-synuclein proteoforms in Parkinson's disease [8][15] - The oncology market is identified as a compelling next opportunity, with plans to evaluate multiple oncology-focused candidate proteins [15] Company Strategy and Development Direction - Nautilus aims to transition from development to active customer engagement, focusing on commercialization and external validation [5][9] - The company plans to progress early access customers into tau services projects and expand early access to include a second proteoform assay focused on an oncology target [25] - The Voyager instrument is expected to be commercially launched in late 2026, with pre-orders opening and installations beginning in early 2027 [25] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the technical foundation required to scale assays and broaden the target portfolio, supporting future commercial deployment [17] - The company expects total operating expenses for 2026 to increase by approximately 15%-20% as it continues investing in platform development [21] - Management highlighted the importance of collaborations and external validation in demonstrating the platform's relevance and potential impact [12][16] Other Important Information - The company has received grant funding from the Michael J. Fox Foundation, expected to total approximately $1.2 million, to support the development of an alpha-synuclein proteoform assay [23] - Nautilus's proprietary Iterative Mapping methodology is designed to analyze single, intact protein molecules at scale, aiming to unlock new biological insights [4][5] Q&A Session Summary Question: What are the next milestones and metrics that will improve based on Q4 technical achievements? - Management highlighted the completion of the tau proteoform assay studies and shared data with early customers, who expressed excitement about the assay's quality [29] Question: Will there be any revenue from the commercial launch later this year? - Management anticipates modest services revenue later in 2026, with a target of around half a million dollars for 2026, while the main revenue ramp will occur in 2027 [39] Question: How is the early access program progressing and what feedback has been received? - Feedback from early customers has been positive, with excitement about the data quality and the ability to forge connections in research that were previously unattainable [42]